Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Phase 1

• Conditions: Breast Cancer; Urothelial Carcinoma
• Interventions: Drug: Trastuzumab deruxtecan; Drug: Nivolumab

• Registration Number: NCT03523572
• Lead Sponsor: Daiichi Sankyo

Brief Summary

This is a study of trastuzumab deruxtecan, which was approved by the FDA (in December 2019) for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens.

Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab.

The study will be done in two parts:

* Part 1 is to identify the recommended dose to use for treatment.

* Part 2 is to find out how well the combination works, and how safe and tolerable it is.

Detailed Description

The purpose of this phase 1b (Part 1, Part 2) study is to assess the combination of a test drug (trastuzumab deruxtecan) with nivolumab in participants with HER2-expressing breast and urothelial cancer who had disease progression during or after prior therapies, did not respond to standard therapies, or for whom no standard therapy is available.

The study will be performed in 2 parts.

* Part 1 is to test different doses of trastuzumab deruxtecan when given along with a fixed dose of nivolumab, and establish the most effective and the maximum/recommended tolerated dose, when used in combination with nivolumab

* Part 2 is to assess the efficacy and safety of this dose combination.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2018-04-30
• Study First Submitted QC: 2018-05-01
• Study First Posted: 2018-05-14
• Study Start: 2018-06-20
• Primary Completion: 2021-07-22
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-11
• Last Update Posted: 2021-08-12
• Study Completion: 2022-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 99

Inclusion Criteria

1. Is the age of majority (adulthood) in their country
2. Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1
3. Has pathologically documented breast cancer or urothelial cancer that is unresectable or metastatic, and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit, and as specified in each study cohort
4. Has an adequate archival tumor sample available for the central laboratory to determine eligibility to participate
5. Has at least 1 measurable lesion per RECIST version 1.1
6. Has cardiac, bone marrow, kidney, liver, blood and clotting test results required per protocol
7. Has had an adequate washout period before enrollment since previous surgery and other treatment
8. If reproduction is possible, agrees to use protocol-defined methods of contraception (or completely abstain from heterosexual intercourse) from screening to at least 7 months for females and males after the last dose of study drug
9. Agrees to avoid harvesting sperm or ova for any reason from screening to at least 7 months for females and males after the last dose of study drug
10. Has a life expectancy of at least 3 months

Read More

Exclusion Criteria

1. Has received prior treatment with nivolumab or trastuzumab deruxtecan

2. Has medical history of myocardial infarction (MI) within 6 months before enrollment, symptomatic congestive heart failure (CHF) (New York Heart Association classes II-IV). Troponin levels above upper limit of normal (ULN) at screening (as defined by the manufacturer) and without any MI-related symptoms should have a cardiologic consultation before enrollment to rule out MI.

3. Has a corrected QT interval by Fredericia (QTcF) prolongation to > 470 ms (females) or > 450 ms (males) based on an average of the screening triplicate 12-lead electrocardiogram

4. Has history of non-infectious interstitial lung disease (ILD/pneumonitis) (that required steroids), has ILD/pneumonitis currently, or it cannot be ruled out by imaging at screening

5. Has a condition (other than active autoimmune disease) that requires systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of starting study treatment

6. Is pregnant or breastfeeding, or planning to become pregnant

7. Is suspected to have certain other protocol-defined diseases based on past medical history, physical exam, blood tests, eye test and imaging at screening period

8. Has received a live vaccine within 30 days before the first dose of study drug

9. Is related to the investigator or another employee of the sponsor or the study site

10. Is pregnant, breastfeeding, or planning to become pregnant

11. Has or had any disease, psychiatric or medical condition, metastatic condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:

    1. safety or well-being of the participant or offspring
    2. safety of study staff
    3. analysis of results

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Dose Expansion - Cohort 1	Nivolumab	Cohort 1 (n=30): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined positive HER2 expression (IHC 3+ or IHC 2+/ISH+) \[as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines\]. These participants have received prior ado-trastuzumab emtansine (T-DM1). Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Dose Expansion - Cohort 1	Trastuzumab deruxtecan	Cohort 1 (n=30): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined positive HER2 expression (IHC 3+ or IHC 2+/ISH+) \[as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines\]. These participants have received prior ado-trastuzumab emtansine (T-DM1). Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Dose Escalation	Trastuzumab deruxtecan	Part 1 will enroll participants meeting the eligibility criteria set up for any of the 4 cohorts of Part 2 specified below using a 3 + 3 + 3 design. Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab will be administered on Day 1 of each 21-day cycle. The recommended dose for expansion (RDE) will be calculated using data collected from this population in the first two cycles. These participants may continue to receive study treatment in subsequent cycles.
Dose Escalation	Nivolumab	Part 1 will enroll participants meeting the eligibility criteria set up for any of the 4 cohorts of Part 2 specified below using a 3 + 3 + 3 design. Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab will be administered on Day 1 of each 21-day cycle. The recommended dose for expansion (RDE) will be calculated using data collected from this population in the first two cycles. These participants may continue to receive study treatment in subsequent cycles.
Dose Expansion - Cohort 2	Trastuzumab deruxtecan	Cohort 2 (n=15): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined low HER2 expression (IHC 1+ or IHC 2+/ISH-), who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive). Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Dose Expansion - Cohort 2	Nivolumab	Cohort 2 (n=15): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined low HER2 expression (IHC 1+ or IHC 2+/ISH-), who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive). Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Dose Expansion - Cohort 3	Trastuzumab deruxtecan	Cohort 3 (n=30): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 2+ or 3+, who received prior platinum-based therapy with documented progression. Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Dose Expansion - Cohort 3	Nivolumab	Cohort 3 (n=30): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 2+ or 3+, who received prior platinum-based therapy with documented progression. Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Dose Expansion - Cohort 4	Trastuzumab deruxtecan	Cohort 4 (n=15): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 1+, who received prior platinum-based therapy with documented progression. Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Dose Expansion - Cohort 4	Nivolumab	Cohort 4 (n=15): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 1+, who received prior platinum-based therapy with documented progression. Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.

Primary Outcome Measures

Name	Time	Method
Part 2: Dose expansion - Objective response rate (ORR) as assessed by Central Imaging Review	6 months after the last participant is enrolled, or when 80% of participants have experienced disease progression or discontinued study treatment, whichever occurs first (within 24 months)	ORR is defined as the percentage of participants with tumor size reduction of a predefined amount and for a minimum time period. ORR includes partial response (PR) and complete response (CR). ORR will be assessed by Central Imaging Review based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Part 1: Number of participants with dose-limiting toxicity at each dose level	2 cycles (within 2 months; each cycle is 21 days)	Categories: Low Dose, High Dose

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DoR)	within 24 months
Disease Control Rate (DCR)	within 24 months
ORR	within 24 months	ORR, as assessed by the investigator based on RECIST Version 1.1.
Progression Free Survival (PFS)	within 24 months	PFS is defined as the time from randomization until objective tumor progression or death, whichever occurs first.
Time to Response based on central review	within 24 months
Overall Survival (OS)	within 24 months	Overall survival is defined as the time from randomization until death from any cause and is measured in the intent-to-treat population.
Number of participants with treatment emergent adverse events (TEAEs) during the trial	at the time of final database lock (anticipated within three years)	Total number of participants in the safety analysis set with TEAEs collected during the trial (including follow-up periods), for inclusion in the database

Trial Locations

Locations (29)

Yale University; 🇺🇸 New Haven, Connecticut, United States

Icahn School of Medicine at Mount Sinai; 🇺🇸 New York, New York, United States

Tennessee Oncology - Sara Cannon Research Institute; 🇺🇸 Nashville, Tennessee, United States

AZ Groeninge; 🇧🇪 Kortrijk, West-Vlaanderen, Belgium

Cliniques Universitaires Saint-Luc; 🇧🇪 Brussels, Belgium

GZA Hospital Campus Sint-Augustinus; 🇧🇪 Wilrijk, Belgium

Charite Campus Benjamin Franklin; 🇩🇪 Berlin, Brandenburg, Germany

Sarah Cannon Research Institute UK; 🇬🇧 London, England, United Kingdom

UCLA - Medical Center; 🇺🇸 Santa Monica, California, United States

Hospital Gregorio Maranon Madrid Spain; 🇪🇸 Madrid, Spain

Institut de Cancerologie de L'Ouest; 🇫🇷 Angers, France

University of Miami Hospital & Clinics/Sylvester Comprehensive Cancer Center; 🇺🇸 Miami, Florida, United States

Norton Cancer Institute; 🇺🇸 Louisville, Kentucky, United States

Gabrail Cancer Center Research; 🇺🇸 Canton, Ohio, United States

Levine Cancer Institute Carolinas Healthcare System; 🇺🇸 Charlotte, North Carolina, United States

Huntsman Cancer Institute; 🇺🇸 Salt Lake City, Utah, United States

University of Washington Medical Center; 🇺🇸 Seattle, Washington, United States

Centre Georges Francois Leclerc; 🇫🇷 Dijon, France

ICO Rene Gauducheau; 🇫🇷 Saint-Herblain, France

University Hospital Frankfurt; 🇩🇪 Frankfurt, Hessen, Germany

Ospedale San Raffaele; 🇮🇹 Milano, Italy

University Cancer Center; 🇩🇪 Dresden, Sachsen, Germany

Fondazione IRCCS Istituto Nazionale dei Tumori; 🇮🇹 Milano, Italy

Azienda Ospedaliera Universitaria Senese U.O.C. Immunoterapia Oncologica; 🇮🇹 Siena, Italy

MD Anderson Cancer Center Madrid; 🇪🇸 Madrid, Spain

Fundacion Jimenez Diaz; 🇪🇸 Madrid, Spain

Royal Marsden Hospital (Surrey); 🇬🇧 London Borough of Sutton, United Kingdom

Hospital Universitario Ramon y Cajal Madrid; 🇪🇸 Madrid, Spain

START Madrid CIOCC; 🇪🇸 Madrid, Spain